Mojtaba Akhtari is an Oncology physician. OpenAlex indexes 182 publications with 2,287 citations (h-index 27).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
988102 Nebraska Medical Ctr
Omaha, NE 681988102
Telephone
402-559-5600Registry record last updated 9 Jun 2014.
Industry payments
50 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year202545 payments$70,545openpaymentsdata.cms.gov ↗
- Syndax Pharmaceuticals, Inc.Program year202529 payments$58,171openpaymentsdata.cms.gov ↗
- Karyopharm Therapeutics Inc.Program year202522 payments$48,424openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
26.7%Kinase inhibitor11.4%Jakafi33%Imbruvica21%Calquence10%Sprycel9%Vonjo9%Iclusig7%Bosulif6%Brukinsa5%Part D<11 patientsThalidomide Analog8.4%Pomalyst63%Lenalidomide20%Revlimid17%Part D<11 patients+ 6 more classes in this area
Nervous system
18.2%Opioid Agonist3.4%Oxycodone Hcl48%Tramadol Hcl33%Fentanyl19%Part D<11 patientsOther antidepressants2.4%Mirtazapine100%Part D≥12 patients+ 8 more classes in this area
Metabolism & gastrointestinal
14.8%Serotonin-3 Receptor Antagonist5.4%Ondansetron Hcl55%Ondansetron Odt45%Part D≥25 patientsPotassium supplement3.2%Potassium Chloride73%Klor-Con 827%Part D<11 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”